Savara Inc. (SVRA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole product candidate is MOLBREEVI (molgramostim inhalation solution), an investigational inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company has no commercial revenue and operates as a single segment. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(30.4) million | $(57.0) million | N/A |
| Net Loss Per Share | $(0.14) | $(0.26) | N/A |
| Operating Expenses | $31.4 million | $59.9 million | N/A |
| Cash & Cash Equivalents | N/A | N/A | $17.4 million |
| Short-Term Investments | N/A | N/A | $129.0 million |
| Total Liquidity | N/A | N/A | $146.4 million |
| Long-Term Debt | N/A | N/A | $29.7 million |
| Accumulated Deficit | N/A | N/A | $(546.3) million |
Material Changes vs. Prior Period
- Expense Growth: Total operating expenses increased by $8.3 million (35.6%) for Q2 2025 compared to Q2 2024.
- R&D Expenses: Rose $3.1 million to $20.8 million, driven by chemistry, manufacturing, and controls (CMC) activities ($3.3 million) and regulatory/quality assurance costs ($1.1 million) to support BLA resubmission.
- G&A Expenses: Surged $5.1 million (92.3%) to $10.7 million, primarily due to strategic personnel additions ($2.5 million) and commercial preparation activities ($1.5 million).
- Debt Restructuring: In March 2025, the company entered a new $200 million credit facility with Hercules Capital. The initial $30 million tranche was used to repay the prior Silicon Valley Bank loan, resulting in a $0.5 million loss on extinguishment of debt recorded in the first half of 2025.
- Investment Portfolio: Short-term investments decreased from $181.2 million (Dec 31, 2024) to $129.0 million (June 30, 2025) due to maturities and purchases, while cash equivalents increased slightly.
Outlook, Risks, and Management Commentary
- Regulatory Status (Critical): In May 2025, the FDA issued a Refusal to File (RTF) letter for the MOLBREEVI Biologics License Application (BLA). The RTF was due to incomplete Chemistry, Manufacturing, and Controls (CMC) data, not safety or efficacy concerns.
- Plan: Savara plans to resubmit the BLA in December 2025 and request Priority Review.
- Liquidity: Management states that current cash and short-term investments ($146.4 million) are sufficient to fund operations for at least the next 12 months. However, additional capital may be required for commercialization if approval is granted.
- Debt Covenants: The new Hercules Loan Agreement includes covenants requiring the maintenance of unrestricted cash equal to 50% of the outstanding principal (increasing to 70% if FDA approval is not achieved) starting April 1, 2026. Future tranches are contingent on FDA approval and revenue milestones.
- Legislative Impact: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed July 4, 2025, regarding changes to R&D capitalization and interest deductions.
Investor Verification Checklist
- BLA Resubmission Timeline: Verify the December 2025 resubmission date and the specific CMC data requirements identified by the FDA.
- Debt Covenant Compliance: Monitor the company's ability to maintain the required cash balance (50-70% of debt principal) starting April 2026, especially given the current burn rate.
- Manufacturing Capacity: Confirm progress with the new drug substance manufacturer (FujiFilm Diosynth) to ensure future supply chain stability.
- Cash Burn Rate: Assess if the current liquidity runway of ~12 months is sufficient given the increased G&A spend for commercial preparation.
- ATM Termination: Note that the "At-The-Market" equity offering agreement with Evercore was terminated in April 2025, limiting one avenue for immediate equity financing.